Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Insmed ( (INSM) ) just unveiled an update.
On August 12, 2025, Insmed announced that the FDA approved BRINSUPRI, the first and only treatment for non-cystic fibrosis bronchiectasis (NCFB) in patients 12 years and older. This approval marks a significant advancement for the approximately 500,000 U.S. patients diagnosed with NCFB, offering a new standard of care by targeting neutrophilic inflammation, a root cause of the disease. The approval is based on positive results from the Phase 3 ASPEN and Phase 2 WILLOW studies, which demonstrated reductions in exacerbations and improvements in lung function. The approval is expected to have a substantial impact on Insmed’s operations and industry positioning, as it addresses a previously unmet need in the treatment of NCFB.
The most recent analyst rating on (INSM) stock is a Buy with a $74.00 price target. To see the full list of analyst forecasts on Insmed stock, see the INSM Stock Forecast page.
Spark’s Take on INSM Stock
According to Spark, TipRanks’ AI Analyst, INSM is a Neutral.
Insmed’s overall stock score is driven by positive technical momentum and promising corporate events, offset by financial challenges and valuation concerns. The earnings call provided a positive outlook, but financial sustainability remains a critical risk.
To see Spark’s full report on INSM stock, click here.
More about Insmed
Insmed Incorporated is a global biopharmaceutical company focused on delivering first- and best-in-class therapies to transform the lives of patients with serious diseases. The company operates in the biopharmaceutical industry, with a market focus on developing treatments for conditions with unmet medical needs.
Average Trading Volume: 3,689,349
Technical Sentiment Signal: Buy
Current Market Cap: $23.86B
Find detailed analytics on INSM stock on TipRanks’ Stock Analysis page.